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Abstract
Background: Despite large interpatient variability in dose response, heparin is utilized for
treatment of venous thromboembolism (VTE). Current data on the optimal heparin dosing in
obese patients are conflicting. Objective: The objective was to evaluate the time and dose
required to achieve a therapeutic activated partial thromboplastin time (aPTT) in nonobese,
obese, and severely obese patients using a pharmacist-directed heparin dosing protocol.
Methods: This was a retrospective cohort study in a single center community hospital inpatient
setting. Adult patients receiving heparin for VTE treatment from July 1, 2013, to July 31, 2015,
were evaluated. Patients were categorized into 3 groups: nonobese (BMI < 30 kg/m2), obese
(BMI = 30-39.9 kg/m2), and severely obese (BMI ≥ 40 kg/m2). Data on height, weight, initial
bolus dose, initial infusion rate, time to therapeutic aPTT, and therapeutic infusion rate were
collected. Dosing body weight (DBW) was utilized for patients 20% over their ideal body weight
(IBW). The primary outcome was time to therapeutic aPTT. Results: Analysis included 298
patients. Median times to therapeutic aPTT (hours:minutes) in the nonobese, obese, and severely
obese were 15:00 (interquartile range [IQR] = 8:05-23:21), 15:40 (IQR = 9:22-25:10), and 15:22
(IQR = 7.54- 23:40), respectively (P = 0.506). There was no difference in bleeding among the
nonobese (14%), obese (13.9%), or severely obese groups (7.9%; P = 0.453). No adverse
thrombotic events occurred during hospitalization. Conclusion: Using a DBW for heparin
dosing in patients 20% over their IBW resulted in similar times to therapeutic aPTT and adverse
events in the nonobese, obese, and severely obese.
Background
Venous thromboembolism (VTE), including deep-vein thrombosis (DVT) and pulmonary
embolism (PE), occurs in 104 out of every 100 000 individuals with up to 4.8% and 7.7%
developing recurrence or adverse bleeding events within 30 days.1 The obese population is
more likely to develop a VTE compared with the nonobese population.2-4 The prevalence of
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obesity (body mass index [BMI] ≥ 30 kg/m2) in the United States continues to rise, with
regional obesity ranging from 25.2% to 31.2% and the Midwest region having the second
highest prevalence at 30.7%.5 Intravenous heparin is frequently a drug of choice in hospitalized
patients with VTE, but weight-based dosing is challenging in obese and severely obese patients
because of the drug’s unpredictable pharmacokinetic properties.
Heparin’s distribution is limited primarily to blood volume. 6,7 Because of limited distribution
into adipose tissue, dosing lower than institutional protocol has been observed in obese patients
to avoid potential overdosing and subsequent adverse bleeding events.8 Subjects included in
early trials establishing weight-based heparin dosing for acute VTE had a mean weight of 80
kg, and these studies did not address dosing in the obese patient population.9,10 More than 2
decades since those studies, the average weight of patients has increased, leaving the question
of what weight is the most appropriate to use when dosing heparin for VTE treatment.11
Implementation of pharmacist-directed heparin therapy using standardized dosing protocols has
been reported.12,13 Pharmacist-directed heparin adjustments lead to an increased number of
patients within therapeutic range compared with physician adjustments.12 A pharmacist-directed
heparin dosing protocol was implemented in our hospital in 2008 (Table 1). The protocol
utilizes actual body weight (ABW) unless the patient is 20% over their ideal body weight
(IBW), at which point a dosing body weight (DBW) is used. Ideal and DBW calculations are
displayed in Table 2. Regardless of weight, the initial bolus dose and initial infusion rate are
limited to 10 000 U and 2500 U/h, respectively. Serial activated partial thromboplastin time
(aPTT) values are used to guide dosing, and dose titrations are made to achieve a therapeutic
aPTT of 57 to 96 s, determined based on laboratory correlation to 0.3 to 0.7 U/mL by an antiXa activity assay. Multiple studies have demonstrated a lower risk of recurrent VTE when
therapeutic aPTTs are achieved rapidly.14,15 With obesity steadily rising in the United States, it
is important to assess optimal drug dosing in this patient population. The objective of this study
was to evaluate time to first therapeutic aPTT and doses required to achieve a therapeutic aPTT
in nonobese, obese, and severely obese patients within our institution when a pharmacistdirected heparin dosing protocol was utilized.

2

Materials and Methods
Study Design and Population
This was a retrospective, single-center cohort study. RxConsult, a proprietary heparin dosing and
monitoring program within the institution, was utilized to identify patients 18 years or older who
were receiving heparin for the indication of VTE treatment, including DVT or PE, and managed
by the pharmacy dosing protocol from July 1, 2013, to July 31, 2015. Indication for heparin
therapy was based on prescriber documentation in the consult to pharmacy for heparin dosing;
therefore, if patients had both DVT and PE, it was not captured for the purposes of this
evaluation. RxConsult is a computer program designed for our institution to assist with dosing
and monitoring of patients receiving therapeutic heparin. When a new patient is initiated on
heparin, a new patient-specific profile must be entered into RxConsult, including the patients’
name, age, sex, height, weight, and indication. RxConsult will calculate the patient’s IBW and
determine if the patient’s ABW is 20% over IBW to determine the correct bolus dose and
infusion rate for the patient based on our dosing protocol. Each aPTT is entered into RxConsult,
and the resultant rate change and/or bolus will be calculated by the program. Patients were
excluded if they had a therapeutic aPTT obtained prior to steady state, which was defined as 6
hours from heparin initiation. RxConsult was used to extract base- line demographics and dosing
information, including age, sex, height, ABW, indication, aPTT values, time to first therapeutic
aPTT, and heparin information, which included initial bolus dose, initial infusion rate,
therapeutic infusion rate, and duration of heparin therapy. Bleeding events and recurrent
thrombotic events were identified from the physician discharge summary, and use of
thrombolytic agents was identified via the electronic medical record. Thrombolytic agents
included systemic alteplase 50 or 100 mg and catheter-directed tenecteplase 2.5, 5, or 10 mg.
Outcomes
The primary outcome was time to first therapeutic aPTT. A therapeutic aPTT was considered 57
to 96 s per institutional standards. Time to therapeutic aPTT was calculated in hours from the
start of bolus dose to the first laboratory-reported therapeutic aPTT. Secondary outcomes
included bleeding or thrombotic events while receiving heparin therapy and percentage of
therapeutic aPTT values. Bleeding was defined as either a drop in hemoglobin from a baseline of
≥2 g/dL with subsequent transfusion of 2 or more units of packed red blood cells (PRBCs) while
on heparin therapy or documented bleeding by the provider in the discharge summary.
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Thrombotic events were defined as documentation of a thrombus in a new location and/or
extension of current thrombus after initiation of heparin.
Data Analysis
Patients were categorized into 3 groups based on BMI: nonobese (BMI < 30 kg/m2), obese (BMI
= 30-39.9 kg/m2), and severely obese (BMI ≥ 40 kg/m2).16 Continuous data were described
using means and SDs for variables considered to be normally distributed and medians and
interquartile ranges (IQRs) for variables considered to be nonnormally distributed. Baseline
demographics and clinical characteristics were compared between groups using analysis of
variance, with Dunnett t-test for post hoc comparisons when needed. χ2 Analyses and KruskalWallis tests were used for nonparametric data. Patients with 3 or more consecutive therapeutic
aPTTs, representing a minimum of 18 hours of a consistent infusion rate, were further analyzed
to determine dose based on ABW, IBW, and DBW. Statistical analysis was conducted using
Statistical Package for Social Sciences version 23.0 (SPSS v23.0). The study was approved by
the institutional review board of the hospital.
Results
A total of 298 patients were eligible for study inclusion. Four patients were excluded for
therapeutic aPTTs obtained prior to steady state, leaving a total of 294 patients for final
analysis. Patient characteristics are dis- played in Table 3. Patients in the severely obese
group (mean ± SD = 57.3 ± 15.6 years) were younger than those in the nonobese (66.2 ± 16.5
years, P < 0.001) and obese groups (65.8 ± 14.5, P = 0.001).

Median time to therapeutic aPTT (hours:minutes) was 15:00 (IQR = 8:05-23:21) for the
nonobese group, 15:40 (IQR = 9:22-25:10) for the obese group, and 15:22 (IQR = 7:54-23:40)
for the severely obese group (P = 0.506). Subgroup analysis was completed for 140 patients who
had at least 3 consecutive therapeutic aPTT values (60 non- obese, 52 obese, and 28 severely
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obese). The mean ± SD infusion rate for nonobese patients was 17.2 ± 5 U/kg/h based on
ABW and 18.4 ± 5.6 U/kg/h based on DBW. Obese patients required a mean ± SD of 15.9 ± 4.4
U/kg/h based on ABW and 20.2 ± 5.7 U/kg/h based on DBW. Severely obese patients required
a mean ± SD of 13.9 ± 3.9 U/kg/h based on ABW and 20.8 ± 6 U/kg/h based on DBW. A total
of 29 patients (55.8%) and 13 patients (46.4%) in the obese and severely obese groups, compared
with 21 (35%) in the nonobese group, required an infusion rate above the initial dose of 18
U/kg/h to achieve consecutive therapeutic aPTT values (P = 0.087).
Table 4 displays efficacy and safety outcomes. Bleeding events occurred in 14%, 13.6%, and
7.9% of nonobese, obese, and severely obese groups, respectively (P = 0.453). Catheter-directed
tenecteplase was given in 17 patients (7 nonobese, 6 obese, and 4 severely obese), and
systemic alteplase was administered in 6 patients (2 nonobese, 1 obese, and 3 severely obese).
Of the patients who received a thrombolytic prior to heparin, 3 nonobese, 3 obese, and 0 severely
obese experienced a bleeding event (33.3%, 42.9%, and 0%, respectively). There were no
thrombotic events documented in any group.

Discussion
Optimal heparin dosing has been controversial since the early 1990s and with increasing
weight trends across the United States, the controversy continues. When heparin is used for the
treatment of VTE, weight-based heparin dosing is recommended because it improves attainment
of target aPTT values.9 However, in patients categorized as obese or severely obese, there is
currently no consensus on the most appropriate weight that should be used for dosing.17 The
nomogram proposed by Raschke et al9 utilizes ABW. However, the study included patients with
a mean weight of 80.9 kg, with only 9 of 62 (14.5%) patients weighing more than 100 kg.9
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Studies by Hull et al14 and Hirsh et al15 suggest that VTE recurrence is reduced when the lower
threshold of therapeutic is exceeded within 24 hours. In obese patients with a BMI >30 kg/m2
treated with heparin for VTE, 89.3% of patients received a bolus dose less than the
recommended 80 U/kg and 76.2% had an initial infusion rate below the recommended dose of 18
U/kg/h. This study describes a prescribing pattern of physicians approximating final therapeutic
infusion rate based on experience instead of adhering to institutional protocol. They separately
interviewed 8 physicians who stated that they were aware of weight-based dosing, but the large
doses required for obese patients was concerning for bleeding events, leading them to decrease
the dose.8 Additionally, 28.6% and 14.3% of the study patients failed to achieve therapeutic
aPTTs within 24 and 48 hours, respectively.8 These results highlight the need to reassess and
clearly define dosing strategies in the increasingly prevalent obese population.
With more than one-third of the US population being obese or severely obese, reevaluating the
appropriate dosing strategy is important.18 Literature on heparin dosing in the obese population is
sparse and is further limited by lack of a standardized definition of obesity and calculation for
DBW. Recent guidance for management of heparin in VTE suggests that a DBW may be an
appropriate approach for obese patients.17 In our cohort, a pharmacist managed heparin dosing
protocol using a DBW for patients weighing greater than 20% over their IBW resulted in a
therapeutic aPTT within approximately 15 hours of infusion initiation for nonobese, obese, and
severely obese patients. Our protocol requires aPTT values to be ordered every 6 hours until a
patient achieves 2 consecutive therapeutic aPTT values. We recognized that laboratory blood
draws are often collected after the ordered time; therefore, a therapeutic aPTT value at
approximately 15 hours likely represents the second aPTT.
To our knowledge, only 1 other study evaluating the use of a DBW for therapeutic heparin
infusions exists. Fan et al19 evaluated time to therapeutic aPTT with ABW and DBW in
preimplementation and postimplementation of an institutional protocol. Their protocol calculated
a DBW using the same formula as in our study. However, a DBW was used for all patients >30%
over IBW, whereas ours utilized DBW for patients 20% over their IBW. The mean weight of the
obese group in the preimplementation phase was 104.7 ± 11.5 kg, and only 31 patients (40.8%)
achieved a therapeutic aPTT within 24 hours. After implementation of the DBW protocol, 44
patients (57.1%) achieved a therapeutic aPTT within 24 hours, and the mean weight of the
postimplementation obese group 138.7 ± 35.6 kg. The infusion rate in the obese group to achieve
a therapeutic aPTT was found to be 18.2 U/kg/h utilizing DBW, which correlates well with the
Raschke nomogram.9,10 Similar to our study, there was no difference found in bleeding events
when using a DBW in obese patients.19
Rapidly exceeding the lower limit of therapeutic aPTT value lowers the risk of recurrent VTE,
thus, making initial dosing and subsequent titrations crucial.8,13,20 Shin and Harthan21 utilized a
weight-based dosing heparin protocol specific to medicine, neurology, and cardiac patients to
evaluate time to exceed the lower limit of therapeutic aPTT. Utilizing ABW, they demonstrated
mean ± SD time (in hours) to therapeutic aPTT for patients <100 kg, 100 to < 125 kg, 125 to <
150 kg, and ≥150 kg of 12.9 ± 9.2, 15.5 ± 12.9, 18.1 ± 15.8, and 23.8 ± 27.9, respectively (P =
0.002), suggesting that body weight affects the time to therapeutic aPTT.21 Because heparin does
not readily distribute into the less vascular adipose tissue, the dose requirements of heparin in
obese patients are not directly proportional to their ABW.
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A subgroup analysis of patients from our cohort with a stable therapeutic infusion demonstrated
that DBW correlated more closely with our protocol dose of 18 U/kg/h. Obese and severely
obese patients required doses of 20.2 ± 5.7 and 20.8 ± 6 U/kg/h, respectively, based on DBW.
The nonobese population also closely aligned with DBW; however, DBW does not differ
significantly from ABW in nonobese patients.
Our study had a slightly higher rate of bleeding events compared with other published studies.
This may have been a result of our definition of bleeding, which included a decrease in
hemoglobin with subsequent transfusion of PRBCs and/or documentation of bleeding in the
discharge summary. Some other studies only included a hemoglobin decrease with transfusion of
PRBCs. Similar to other studies evaluating heparin in obese populations, no difference in
bleeding events was observed between the nonobese, obese, or severely obese groups.19,21 We
evaluated additional thrombotic events until patient discharge and found no additional
thrombotic events in any of the patients included, which may be limited by our definition. We
further analyzed bleeding in patients who received thrombolytic agents prior to heparin
initiation. No difference in bleeding was found between the nonobese, obese, or severely obese
patients, with 33.3% (3/9), 42.9% (3/7), and 0% (0/7), respectively, in patients who received a
thrombolytic.
Our study is limited by the single-center cohort and retrospective design. Much like the current
literature, our study is also limited by the overall small sample size and the lower number of
patients in the severely obese weight category. Use of the discharge summary to identify
documentation of bleeding and/or thrombotic events may have underestimated adverse bleeding
events and/or secondary thrombotic events. Additionally, our primary outcome of time to
therapeutic aPTT does not necessarily correlate with achievement of steady state, especially
because only 47.6% of our patient population had 3 consecutive therapeutic aPTTs, and we did
not assess time to exceed the lower limit of therapeutic aPTT. We did not include baseline
characteristics that might put patients at increased risk of VTE, such as active cancer or
preexisting hypercoagulability states, or increased risk for bleeding, including concomitant use
of anticoagulants and antiplatelet agents or preexisting renal dysfunction. We also did not
investigate indications for administration of thrombolytic agents.
Conclusion
The median time to therapeutic aPTT did not differ in nonobese, obese, or severely obese
patients when a DBW was utilized in patients weighing 20% over their IBW. Our findings
support the use of a DBW for patients weighing 20% over their IBW.
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